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A B S T R A C T
This case is the ﬁrst report of a patient who had phenobarbital (PB) withdrawal seizures after having been
seizure-free for 3 years following temporal lobe surgery. The patient had been taking PB for 14 years
when a gradual taper of PB was started. When PB was at 60 mg/d, a titration of lamotrigine (LTG) was
started. However, typical complex seizures occurredwhen the patient was on PB 60 mg/d, alongwith LTG
25 mg/d. PB was increased back to 90 mg/d and levetiracetam (LEV) was titrated. Seizures appeared
when the patient was on PB 30 mg/d and LEV 750 mg BID and continued for 3weeks after PBwas stopped
and the patient was on LEV 1000 mg BID. For the following 6 months, her aura frequency remained
elevated in comparison to her baseline aura of two auras per month for the previous year before the start
of the PB taper. She was followed for 24 months after her last PB withdrawal seizure. During the last 8
months, her aura frequency returned to her baseline. As suggested by animal studies, the PB withdrawal
seizures and increase in aura frequency in this patient may be explained by changes in her levels of
GABAA receptor subunits.
 2008 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
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Because of the increased risk of fractures, osteopenia, and
osteoporosis associated with long-term phenobarbital (PB) ther-
apy,1–3 we decided to slowly withdraw the patient from PB after
she had been seizure-free for 3 years following right anterior
temporal lobectomy. A previous study reported an increase seizure
frequency in patients tapered from PB or primidone, while
stabilized on another anti-epileptic drug (AED).4 Our report is
the ﬁrst study in a patient who had been seizure-free for several
years before the initiation of the PB taper and who once again
became seizure-free after full PB discontinuation.
PB withdrawal in rodents has been associated with a decrease
in the number of GABA A receptors (GABAAR).
5 There was a
45% decrease in the a1 subunit protein levels of the GABAAR in
the whole hippocampus in rat pups that had been exposed to PB
for 30 days in comparison to vehicle-treated controls.6 This
ﬁnding suggests that chronic PB exposure results in changes in the
GABAAR and that change in the expression of the subunits of
the GABAAR may correlate with the presence of PB withdrawal
seizures.* Corresponding author. Tel.: +1 585 275 5600; fax: +1 585 273 2652.
E-mail address: Jean_Bidlack@urmc.rochester.edu (J.M. Bidlack).
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A 51-year-old female patient, seizure-free for 3 years following
removal of a cavernous angioma of her right anterolateral temporal
lobe, had been taking PB for 11 years before surgery and was
maintained on PB 150 mg/d for 3 years after surgery. We decided
to taper PB and to replace it with an anticonvulsant not associated
with the above risks. The patient kept accurate daily records of
auras and seizures on a long-term continuous basis.
Because PB induces the UDP-glucuronosyltransferase 1 family
of enzymes that glucuronidate lamotrigine (LTG), we decided to
taper PB from 150 to 60 mg/d before initiating the LTG titration.
The PB dosewas reduced by 30 mg every 3weeks. For the 16weeks
preceding the initiation of the PB taper, the patient averaged two
psychic auras per month, which was the baseline that she had
maintained for the previous year, but she remained seizure-free.
When the patient had tapered PB to 60 mg/d, the LTG titration
was initiated. LTG was increased by 25 mg per week until a dose of
100 mg BID was achieved. However, as shown in Fig. 1, when the
patient reached doses of PB 60 mg/d and LTG 25 mg BID, complex
partial seizures occurred. At the time, it was not known whether
these seizureswere PBwithdrawal seizures or the reinstatement of
her complex partial seizures because the symptoms of these
seizures were virtually identical to her pre-operative seizures. Her
PB blood level was 7mg/ml when the seizures started (Fig. 1).
When the patient had been seizure-free on 150 mg/d of PB, hervier Ltd. All rights reserved.
Fig. 1. PB withdrawal seizures as a function of the daily doses of PB and LTG. PB was
tapered by 30 mg every 3 weeks. On the second week that the patient was on PB
60 mg/d, a LTG titrationwas started with the ﬁrst week being a daily dose of 25 mg/
d. Data are reported as the number of seizures per week.
Fig. 3. Aura frequency during the 24 months after cessation of PB withdrawal
seizures. After the PB withdrawal seizures had stopped, the frequency of auras was
recorded. Before the PB taper, when the patient was taking PB 150 mg/d, her
baseline aura frequency for more than a year was two auras per month. Data are
reported as the number of auras during the previous 30 days. Data were collected
for 24 months after her last PB withdrawal seizure.
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PB dosewas increased back to 90 mg/d, a dose that kept the patient
seizure-free. Conversion to LTG ultimately failed because of rash.
The goal remained to switch from PB to an AED without the
risks associatedwith an AED that induces hepaticmetabolism. Five
weeks after LTG was stopped, levetiracetam (LEV) was started. The
patientwas on PB 90 mg/d, and LEVwas increased by 125 mg every
5 days until a dose of 500 mg BID was obtained. The patient
averaged approximately one aura per week. After the patient was
taking LEV 500 mg BID, the PB taper was attempted the second
time at a slower rate. PB was reduced by 15 mg every 3 weeks,
which was half the rate of the initial PB taper. At a dose of PB
45 mg/d and LEV 500 mgBID, the frequency of auras increased. LEV
was increased from 500 to 750 mg BID, while the PB taper
continued. Complex partial seizures started when the patient was
taking PB 30 mg/d and LEV 750 mg BID (Fig. 2). Because of the
seizures, LEV was increased further to 1000 mg BID. When the
patient was on PB 15 mg/d and LEV 1000 mg BID, four seizures
occurred over a 3-week period (Fig. 2). She had an additional four
seizures during the ﬁrst week after discontinuing PB. The seizures
continued for 3 weeks after discontinuation then stopped (Fig. 2).
The patient has been maintained on LEV 1000 mg BID. There have
been no further seizures during 24 months of follow-up.
The frequency of the patient’s auras remained above her base-
line of two auras per month for 6 months immediately followingFig. 2. PB withdrawal seizures as a function of the daily doses of PB and LEV. PB was
tapered by 15 mg every 3 weeks. The dose of LEV was increased as shown in the
graph. Data are reported as the number of seizures per week.cessation of PBwithdrawal seizures (Fig. 3). The patient experienced
insomnia andanxietywhile taperingPB. Insomniaandan increase in
aura frequencywere theﬁrstphysical signsofPBwithdrawaldespite
the very slow taper. Insomnia abated shortly after complete
withdrawal from PB. Anxiety ﬁrst occurred when the patient had
tapered to PB 30 mg/d. Some anxiety remained for the same 6-
month period after seizure cessation, when therewas an increase in
aura frequency. Starting at 7 months after PB cessation, her aura
frequency decreased to her baseline aura frequency of twoauras per
month (Fig. 3) and her anxiety symptoms resolved.
3. Discussion
This case demonstrates a ‘‘threshold’’ for PB withdrawal
seizures at 30–60 mg/d and cessation of withdrawal seizures
following PB discontinuation. At a dose of PB 90 mg/d, the patient
had a plasma PB level of 11 mg/ml (Fig. 1). Assuming clearance did
not change, withdrawal seizures appeared when the PB level was
5–8 mg/ml.Withdrawal seizures were not controlled by either LTG
at low dose or LEV at high dose but ceased 3 weeks post-complete
withdrawal. Although it is possible that other factors such as
incomplete resection of pathologic tissue, contralateral or extra-
temporal involvement might be responsible for seizure reoccur-
rence, neither the post-operative MRI nor the pre-operative EEG,
respectively, supported these possibilities. While many endogen-
ous and exogenous stresses such as illness, hormonal changes,
stress, and fatigue may trigger seizures in patients with epilepsy,
the only time our patient had clinical seizures was during and
immediately following the tapering of PB.
A previous study reported PB withdrawal seizures when
patients with refractory seizures were being rapidly tapered from
PB or primidone, while stabilized on another AED.4 There was a
tendency for the seizures rates to be the highest when the PB blood
levels passed through the range of 15–20mg/ml.4 The present case
demonstrates that despite a very slow PB taper over several
months in a seizure-free patient, withdrawal seizures may occur
for several weeks before remission. The occurrence of PB with-
drawal seizures does not mean PB withdrawal will not be
ultimately successful.
After the 7 weeks of PB withdrawal seizures in the presence of
LEV 1000 mg BID, the frequency of auras remained elevated for
another 6 months before returning to baseline. A long period of
withdrawal symptoms has been observed during the tapering of
other CNS drugs that produce physical dependence. Protracted
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benzodiazepines have been reported.7 Smith and Wesson [8]
observed that symptoms, such as anxiety, insomnia, and par-
esthesia, after withdrawal from low-dose benzodiazepine typically
take 6–12 months to subside completely. In our patient, it took 7
months for her aura frequency to return to baseline.
Molecular changes in the GABA system probably account for
many symptoms associated with PB withdrawal. Approximately
43% of the GABAAR in mammalian brain is comprised of two a1
subunits, two b2 subunits and one g1 subunit. In humans with
temporal lobe epilepsy (TLE) and in rodent models of TLE, there
was a reduced expression of GABAAR a1 subunits and increased
expression of GABAARa4 subunits in the dentate gyrus of epileptic
individuals.9,10 Binding of the GABA agonist, [3H]muscimol, to
GABAAR in rat brain homogenates was reduced by 25% in
withdrawing animals for up to 10 days after chronic PB exposure.4
This ﬁnding suggests downregulation of the GABAAR during PB
withdrawal. GABA agonists are known to cause downregulation of
the GABAAR through endocytosis of GABAAR via clathrin-coated
pits is indicated by the interaction between GABAAR and the
adapter protein AP2 and is known to require the g2 subunit and
dynamin. Endosomal GABAAR are targeted for degradation or are
possibly held and recycled back to the surface with the help of Plic-
1.11 Similarly, prolonged exposure to ethanol, which also activates
the GABAAR,
12 has been shown to increase the endocytic
internalization of a1 subunits.13
Therewas45% decrease in thea1 subunit protein levels of the
GABAAR in the whole hippocampus in rat pups that had been
exposed to PB for 30 days in comparison to vehicle-treated
controls.6 An adeno-associated virus type 2 containing the a4
subunit gene promoter has been used to drive transgene
expression in dentate gyrus of rats after status epilepticus (SE).
Enhanced expression of the GABAAR a1 subunit in the dentate
gyrus resulted in a threefold increase in mean seizure-free time
after SE and a 60% decrease in the number of rats developing
recurrent seizures in the ﬁrst 4 weeks after SE.14 In contrast,
withdrawal from a positive modulator of GABAAR activity, such as
benzodiazepines, ethanol and neurosteroids, induces a decrease in
the levels of thea1 subunit and an increase in the expression of the
a4 subunit of the GABAAR.
15 Collectively, previous studies have
shown that changes in the subunit composition of the GABAAR
occur before and during PBwithdrawal.6 Based on rodent studies, a
downregulation of the GABAAR, particularly the a1 subunit, would
be associated with an increase in the frequency of withdrawal
seizures and auras.
In conclusion, this well-documented case report demonstrates
the long timeline of PB withdrawal seizures. In our patient, they
began when her PB dose had been reduced by approximately 50%and were not related to speed of PB withdrawal. In addition, PB
withdrawal seizures occurred for 7 weeks following complete
withdrawal; auras remained above baseline rate for 7 months as
did other common symptoms of PB withdrawal. The protracted
seizures and auras may be explained by the alteration in the
GABAAR subunits and the long time required for it to revert to its
normal state. Withdrawing patients from PB can be done but
should be done slowly. Despite seizures onwithdrawal, the process
may ultimately be successful.
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